Merck presents positive results from phase 1/2 study evaluating V116
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Expanding diagnostics footprint in East India
Subscribe To Our Newsletter & Stay Updated